20:42 , Oct 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Graft-versus-host disease (GvHD) Mouse studies suggest RSPO1 and DEFA1 could help prevent GvHD-induced gut dysbiosis. In a mouse model of GvHD, RSPO1 delivered before and after disease induction decreased dysbiosis and intestinal pathology compared...
08:00 , Jan 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Chemokine CC motif ligand 5 (RANTES; CCL5); defensin α 1 (DEFA1; HNP-1)

Cardiovascular disease INDICATION: Inflammation; myocardial infarction (MI) Cell and mouse studies identified a peptide inhibitor of DEFA1- RANTES binding that could help treat MI and inflammation. In a proximity ligation assay in human endothelial cells,...
07:00 , Jun 25, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: SNPs within defensin α 1 (DEFA1; HNP-1)/defensin β 1 (DEFB1) gene cluster and other loci as risk markers for IgA nephropathy

Biomarkers DEFA1 DEFB1 defensin HNP-1 Sun Yat-sen University...
08:00 , Jan 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Sepsis Bacterial lipid II In silico, in vitro and mouse studies suggest a compound that mimics the antimicrobial peptide defensin a1 (DEFA1; HNP-1) could...